Clinical trial
The Differences Between Insulin Glargine U300 and Insulin Degludec U100 in Impact on the Glycaemic Variability, Oxidative Stress, Arterial Stiffness and the Lipid Profiles in Insulin naïve Patients Suffering From Type Two Diabetes Mellitus
NCT04692415 is registered in ClinicalTrials.gov with University of Split, School of Medicine as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- The Differences Between Insulin Glargine U300 and Insulin Degludec U100 in Impact on the Glycaemic Variability, Oxidative Stress, Arterial Stiffness and the Lipid Profiles in Insulin naïve Patients Suffering From Type Two Diabetes Mellitus
- Lead sponsor
- University of Split, School of Medicine
- Phase
- Phase 4
- Overall status
- Completed
- Start date
- December 15, 2018
- Completion date
- June 27, 2019
- Enrollment
- 25 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.